Skip to content

Study · Animal study (in vivo) · rat · 2014

5 results

Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.

Cai HY, Hölscher C, Yue XH, Zhang SX, Wang XH, Qiao F, Yang W, Qi JS

Neuroscience27 Feb 2014Cited by 93 (Europe PMC)

PMID24583037 (opens in a new tab)DOI10.1016/j.neuroscience.2014.02.022 (opens in a new tab)PepBankPUB-24583037
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, lixisenatide prevented amyloid β25-35-induced spatial learning and memory impairment.

    In plain wordsIn rats, lixisenatide prevented learning and memory impairment compared with amyloid injury without lixisenatide.

    Peptide
    Lixisenatide
    Outcome
    DecreaseSpatial learning and memory impairment
    Study

    ratn: not reported in source

    Amyloid β25-35-induced impairment
    Comparator
    Amyloid β25-35 injury without lixisenatide
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    (1) bilateral intrahippocampal injection of Aβ25-35 resulted in a significant decline in spatial learning and memory of rats, as well as a suppression of in vivo hippocampal long-term potentiation (LTP); (2) lixisenatide treatment effectively prevented the Aβ25-35-induced impairments;
    1 context sentence
    Summary · context
    In the present study, we report for the first time the effects of lixisenatide on the amyloid β (Aβ) protein-induced impairments in spatial learning and memory of rats, and investigated its electrophysiological and molecular mechanisms.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, lixisenatide prevented amyloid β25-35-induced suppression of hippocampal long-term potentiation.

    In plain wordsIn rats, lixisenatide prevented reduced hippocampal signal strengthening compared with amyloid injury without lixisenatide.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHippocampal long-term potentiation
    Study

    ratn: not reported in source

    Amyloid β25-35-induced impairment
    Comparator
    Amyloid β25-35 injury without lixisenatide
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    (1) bilateral intrahippocampal injection of Aβ25-35 resulted in a significant decline in spatial learning and memory of rats, as well as a suppression of in vivo hippocampal long-term potentiation (LTP); (2) lixisenatide treatment effectively prevented the Aβ25-35-induced impairments;
    1 context sentence
    Summary · context
    In the present study, we report for the first time the effects of lixisenatide on the amyloid β (Aβ) protein-induced impairments in spatial learning and memory of rats, and investigated its electrophysiological and molecular mechanisms.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, lixisenatide inhibited amyloid β25-35-induced GSK3β activation.

    In plain wordsIn rats, lixisenatide reduced GSK3β activation compared with amyloid injury without lixisenatide.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGSK3β activation
    Study

    ratn: not reported in source

    Amyloid β25-35-induced impairment
    Comparator
    Amyloid β25-35 injury without lixisenatide
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    (3) lixisenatide inhibited the Aβ25-35 injection-induced activation of glycogen synthase kinase 3β (GSK3β), with a significant increase in the phosphorylation of ser9 and a significant decrease in the phosphorylation of Y216.
    1 context sentence
    Summary · context
    In the present study, we report for the first time the effects of lixisenatide on the amyloid β (Aβ) protein-induced impairments in spatial learning and memory of rats, and investigated its electrophysiological and molecular mechanisms.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, lixisenatide significantly increased GSK3β ser9 phosphorylation after amyloid β25-35 injury.

    In plain wordsIn rats, lixisenatide increased GSK3β ser9 phosphorylation compared with amyloid injury without lixisenatide.

    Peptide
    Lixisenatide
    Outcome
    IncreaseGSK3β ser9 phosphorylation
    Study

    ratn: not reported in source

    Amyloid β25-35-induced impairment
    Comparator
    Amyloid β25-35 injury without lixisenatide
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    (3) lixisenatide inhibited the Aβ25-35 injection-induced activation of glycogen synthase kinase 3β (GSK3β), with a significant increase in the phosphorylation of ser9 and a significant decrease in the phosphorylation of Y216.
    1 context sentence
    Summary · context
    In the present study, we report for the first time the effects of lixisenatide on the amyloid β (Aβ) protein-induced impairments in spatial learning and memory of rats, and investigated its electrophysiological and molecular mechanisms.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats, lixisenatide significantly decreased GSK3β Y216 phosphorylation after amyloid β25-35 injury.

    In plain wordsIn rats, lixisenatide decreased GSK3β Y216 phosphorylation compared with amyloid injury without lixisenatide.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGSK3β Y216 phosphorylation
    Study

    ratn: not reported in source

    Amyloid β25-35-induced impairment
    Comparator
    Amyloid β25-35 injury without lixisenatide
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    (3) lixisenatide inhibited the Aβ25-35 injection-induced activation of glycogen synthase kinase 3β (GSK3β), with a significant increase in the phosphorylation of ser9 and a significant decrease in the phosphorylation of Y216.
    1 context sentence
    Summary · context
    In the present study, we report for the first time the effects of lixisenatide on the amyloid β (Aβ) protein-induced impairments in spatial learning and memory of rats, and investigated its electrophysiological and molecular mechanisms.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.